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Financial constraints versus public desire for more-generous healthcare create a 
difficult dilemma for countries globally. As each market strives to manage its pre-
scription drug market, highly specific market access requirements and challenges 
abound for drugmakers. Innovative developers must engage with payers much 
earlier in the product development cycle in order to optimize trial design to satisfy 
specific MA and payer requirements on demonstrating innovation (e.g. selecting 
the appropriate comparator, targeting the correct/local patient population, gather-
ing the most compelling head-to-head). By exploring how pricing and reimburse-
ment (P&R) decisions are made in many major and developing markets around the 
world, we have developed a Country Archetypes model that identifies similarities 
among payer requirements, and, vitally, determines where product value messaging 
can be leveraged to optimize market access strategy. Data on payer type and drug 
review processes, payer fragmentation, percentage of individuals covered by a health 
insurance system, size of the pharmaceutical market, percentage of government 
and individuals in healthcare spending, and use as a reference country for other 
nations were collected for 27 of the largest pharmaceutical markets in the world. 
Considerations around free pricing, health technology assessment, and review of 
pharmacoeconomic and outcomes research data rules were made, and further seg-
mentations on decision impact, size of reimbursable market, out-of-pocket costs, 
role of health insurance and market fragmentation applied. Ultimately, from the 
27 nations examined, six groups emerged, each comprising countries with com-
monalities across all measures, albeit distinct profiles that affect P&R: Accountants, 
Pragmatists, Evidence seekers, Deal-makers, Ceiling setters, and Independents. 
Our Country Archetype model is intended to help multinational pharmaceuti-
cal companies prepare for local reimbursement evaluations, and pinpoint where 
decision-makers can be found. With classifications based on the most important 
set of reimbursement criteria necessary to attain favorable access in each market, 
the keys to access can be found and turned.
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Kazakhstan is an upper-middle-income country with per capita GDP of nearly US$13 
thousand in 2013. Kazakh’s public healthcare system – UNHS (Unified National Health 
System) – aims to deliver healthcare coverage to the whole population. Despite this 
objective, only two thirds of interventions (on average) in UNHS were fully covered by 
public funding, while the remaining were funded by patients through either private 
health schemes or out-of pocket payments. Finding better ways to manage the use 
and cost of health technology is a high priority for Kazakh policy makers. As health 
policy makers face increasing pressure from the public to make explicit determina-
tions about how and which technologies will be covered within the state guaranteed 
benefits package, the profile and scrutiny of HTA activity has, consequently, also 
increased. Even though there has been a rapid growth of HTA activities, HTA has not 
been developed as much as expected. There are several possible reasons why the MoH 
did not develop the strategy adopting HTA. First, comprehensive evaluation through 
HTA would make clear the failure of health policy previously implemented. Second, 
the MoH still relied on the traditional consensus method based on opinion or experi-
ence, which favors incremental and marginal changes, rather than a drastic reform. 
Third, there has been a power game of politics between innovative and conservative 
groups in the MoH. The Kazakh health care system needs HTA to be constructive to 
enable decision makers to make informed decisions with regard to the adoption of 
health technology. The development and promotion of clear criteria for selection of 
HTA topics is, therefore, essential to promote the efficient use of HTA information for 
decision making with respect to setting ultimate goals for HTA.
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Despite the average Indian patient becoming more knowledgeable with regards to 
his/her health, disease and treatment options, many Indian physicians still depend 
heavily on disease-related outcome measures to take health-care related decisions, 
and give minimal importance to patient-reported outcomes (PROs) pertaining to the 
effect of the healthcare interventions on the patient’s well-being. This trend is also 
seen in clinical trials (CTs) in India where PROs, if used, are only secondary to disease-
related outcomes. As on today, there are no commendable patient-centered outcome 
researches (PCORs) happening in India. With the arrival of PCOR Institute (PCORI) in 
the US, PROs are now getting the attention that they deserve; however, in India the 
concept is yet to catch up. PROs have a significant role in CTs, such as determination 
of patient eligibility, determination of patient compliance, as a study endpoint, deter-
mination of health-related quality of life (HRQoL), and assessing economic burden and 
indirect impact of disease and treatment. Implementation of regular PROs assessment 
in clinical trials can help in determining the negative effects of therapy, comparing 
two standard therapies having similar survival outcomes, finding out whether a new 
therapy is preferable to standard therapy, determining whether a therapeutic regimen 
is better than supportive care only, when survival time is short, and making the com-
munication easier in clinical practice. Improved design and proper implementation 
of PROs in clinical trials (CTs) are necessary to provide high quality evidence to syn-
thesize clinical practice guidelines. Implementation of PROs in CTs should be made 
mandatory for pharmaceutical companies to prove their label claims, especially in 
a country like India where the generic market is strong and widespread. Also, data 
obtained from PROs in CTs should be made the source document for making health-
related decisions at all levels in India.
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BACKGROUND: The critical importance and use of health technology assessment 
in health care decisions towards improved health is practically nonexistent in 
many Central American and Caribbean countries. A culture with a health eco-
nomics mindset that enhances access to new technologies is needed, one that 
increases the knowledge and application of economic evaluation amongst health 
stakeholders to make cost-effective decisions that improve health. OBjeCtives: In 
general, to find new ways to make new drugs and technologies available to patients, 
healthcare providers, governments and society as a whole. Specifically, to develop 
a practical guideline for the pharmaceutical and healthcare industries to make 
new technologies available to patients in resource-limited settings. MethODs: A 
needs assessment was conducted amongst key internal (pharmaceutical industry) 
and external stakeholders (public, private and non-profit institutions) in Central 
America and the Caribbean to gain insight into their decision-making basis and 
behaviors regarding new technology acquisition. A literature review of lessons 
learned and best practices around the world complemented the information col-
lected from local stakeholders. ResUlts: A pivotal concept was created and coined 
as Pillars of Cost-Effectiveness. This concept advocates for three types of “effective-
ness” comprising each three types of strategic considerations as follows: 1. Clinical 
Effectiveness: safety, efficacy and quality, 2. Medical Access Effectiveness: value-
added services, impact information dissemination and managed-entry agreements, 
and 3. Economic Effectiveness: burden of disease data, cost-effectiveness evidence 
and budget impact analysis. CONClUsiON: The Pillars of Cost-Effectiveness may 
serve as the “New Technology Cost-Effectiveness Checklist” to make evidence-based 
decisions in resource-limited settings. In turn, it may become the tool to assess 
and assure the universal goals of patients, providers, payers and policy-makers to 
(1) get the best drug and technology quality at the lowest cost and with reasonable 
access, and (2) enhance healthcare partnerships and solutions towards improved 
individual and population health outcomes.
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BACKGROUND: Cancer is an increasing problem in developing countries. It ranks 
as the fourth leading cause of death in the eastern Mediterranean region and is 
one of the leading causes of death in the world. Although, in developing countries, 
incidence of cancer is still below that in the developed ones, they are expected to 
experience an increase in the burden of cancer, which if added to the more limited 
resources available, requires immediate intervention. Multiple projects had been 
initiated, but facing technical and other problems related to resources and equity 
leads them to be ineffective and inefficient. Objectives: Developing the nucleus for 
numerous Oncology Hospital-Based HTA (HB HTA) units as a tool for evidence based 
decision making and better utilization of resources to reach for a highly performing 
healthcare system. MethODs/RespONsiBilities: Decentralized HB HTA emerges 
from the need to take tailored healthcare decisions in a short period of time. These 
decisions should make use of local intrinsic data, providing solutions that are com-
patible with the hospital’s values and priorities. Generally, responsibilities include 
receiving requests (according to certain technical, medical, clinical, economic, and 
social aspects) from Healthcare Practitioners and/or decision makers in relation 
to the adoption of certain technology/intervention. This unit then aggregates all 
the available data (from primary and secondary sources), synchronize and analyze 
them appropriately, resulting in site-relevant clinical and economic final assess-
ments. DisCUssiON: A single university (department) experience as a nucleus for 
HB HTA is centered on the three main interest of a university hospital: Research, 
Education and Clinical practice. It depends on the presence of: 1- A chemotherapy 
independent unit which can provide standardized regimens based on the HTA-based 
decisions, 2- Well-developed oncology electronic medical record to insure standard-
ized data collection and rapid communication between different departments, 3- an 
E-learning program, and 4- a clinical research unit.
PHP189
AugMenTing THe regulATory requireMenTs of MediCATion THerAPy 
MAnAgeMenT To iMProve ProgrAM effiCienCy And ouTCoMes
Mbagwu G.1, Godley P.2
1The University of Texas at Austin, Austin, TX, USA, 2Scott & White Health Plan, Temple, TX, USA
The Medicare Modernization Act of 2003 requires prescription drug plans to pro-
vide medication therapy management services to eligible Part D beneficiaries. 
In 2010, in an attempt to increase consistency among programs, the Centers for 
Medicare and Medicaid Services (CMS) expanded the regulatory requirements 
associated with medication therapy management (MTM). After evaluating the 
outcomes of MTM since its implementation in 2006, CMS concluded that the pro-
gram has fallen short of expectations. On implementation of MTM, CMS projected 
that 25 percent of Medicare beneficiaries would qualify for MTM based on the 
proposed eligibility criteria. In reality, the percent of MTM eligible beneficiaries 
has fallen far below that approximation. Among members who meet eligibility 
criteria, MTM completion rates remain around 20 percent, on average. CMS also 
notes that certain racial and ethnic disparities continue to exist in MTM eligibil-
ity. Specifically, African American and Hispanic beneficiaries are less likely to 
